MX2022009904A - Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial. - Google Patents

Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial.

Info

Publication number
MX2022009904A
MX2022009904A MX2022009904A MX2022009904A MX2022009904A MX 2022009904 A MX2022009904 A MX 2022009904A MX 2022009904 A MX2022009904 A MX 2022009904A MX 2022009904 A MX2022009904 A MX 2022009904A MX 2022009904 A MX2022009904 A MX 2022009904A
Authority
MX
Mexico
Prior art keywords
treatment
urothelial carcinoma
agents
tyrosine kinase
kinase inhibitors
Prior art date
Application number
MX2022009904A
Other languages
English (en)
Spanish (es)
Inventor
Manish Monga
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022009904A publication Critical patent/MX2022009904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MX2022009904A 2020-02-12 2021-02-11 Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial. MX2022009904A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062975526P 2020-02-12 2020-02-12
US202063025817P 2020-05-15 2020-05-15
US202063055187P 2020-07-22 2020-07-22
US202063078205P 2020-09-14 2020-09-14
US202063078736P 2020-09-15 2020-09-15
US202063083316P 2020-09-25 2020-09-25
PCT/EP2021/053384 WO2021160763A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
MX2022009904A true MX2022009904A (es) 2022-08-25

Family

ID=74666674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009904A MX2022009904A (es) 2020-02-12 2021-02-11 Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial.

Country Status (15)

Country Link
US (1) US20230135136A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103184A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023513298A (cg-RX-API-DMAC7.html)
KR (1) KR20220140777A (cg-RX-API-DMAC7.html)
CN (1) CN115087446A (cg-RX-API-DMAC7.html)
AU (1) AU2021219948A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163407A1 (cg-RX-API-DMAC7.html)
IL (1) IL295515A (cg-RX-API-DMAC7.html)
JO (1) JOP20220181A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009904A (cg-RX-API-DMAC7.html)
PH (1) PH12022552091A1 (cg-RX-API-DMAC7.html)
TW (1) TWI900527B (cg-RX-API-DMAC7.html)
UY (1) UY39080A (cg-RX-API-DMAC7.html)
WO (1) WO2021160763A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib
WO2025046898A1 (ja) * 2023-08-31 2025-03-06 大鵬薬品工業株式会社 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
KR20240064733A (ko) * 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Also Published As

Publication number Publication date
CA3163407A1 (en) 2021-08-19
TW202140012A (zh) 2021-11-01
UY39080A (es) 2021-10-29
BR112022015825A2 (pt) 2022-10-04
US20230135136A1 (en) 2023-05-04
EP4103184A1 (en) 2022-12-21
JP2026097931A (ja) 2026-06-16
TWI900527B (zh) 2025-10-11
JOP20220181A1 (ar) 2023-01-30
WO2021160763A1 (en) 2021-08-19
KR20220140777A (ko) 2022-10-18
PH12022552091A1 (en) 2023-11-20
AU2021219948A1 (en) 2022-10-06
CN115087446A (zh) 2022-09-20
JP2023513298A (ja) 2023-03-30
IL295515A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
PH12022552091A1 (en) Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
MX2022011141A (es) Anticuerpos anti-coronavirus y metodos de uso.
MY203469A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
PH12021552675A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
MX2022010977A (es) Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2022010975A (es) Inhibidores de egfr, kras, braf y otras dianas y uso de estos.
MX2021006731A (es) Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
CR20240296A (es) Inhibidores parp1
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
PH12021552352A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MX2022013876A (es) Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
CR20220660A (es) Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
WO2020257823A3 (en) TGF-β RECEPTORS AND METHODS OF USE
TNSN04015A1 (en) Combination therapy for the treatment of cancer
Agarwal et al. Is EGFR really a therapeutic target in head and neck cancers?
MX2022016232A (es) Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
MX2023004342A (es) Politerapia de antagonistas de union al eje de pd-1 e inhibidores de lrrk2.
MX2025010212A (es) Uso de inmunoconjugados anti-ceacam5 para el tratamiento de canceres neuroendocrinos que expresan ceacam5
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2